Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06333509
Other study ID # CT071-HM-01
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 15, 2024
Est. completion date December 31, 2027

Study information

Verified date March 2024
Source CARsgen Therapeutics Co., Ltd.
Contact CARsgen US
Phone CentralNumber
Email clinicalUS@carsgen.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.


Description:

This is an open-label, multicenter, Phase 1/2 trial of CT071 in adult participants with relapsed or refractory multiple myeloma (RRMM) or relapsed or refractory primary plasma cell leukemia (RRpPCL). The study will be conducted in two phases. Phase 1 of the study will be dose escalation followed by dose expansion. After recommended Phase 2 dose is identified in Phase 1, the enrollment of Phase 2 will start. Following consent, enrolled subjects will undergo apheresis to collect cells for manufacture of the CAR-T cells. Following the manufacture of the CAR-T cells, subjects will receive lymphodepletion prior to CAR T-cell infusion. All subjects who complete the study, as well as those who withdraw from the study after receiving CAR T-cell infusion for reasons other than death or meeting the early termination criteria, will be asked to undergo a 15-year long-term follow-up.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 166
Est. completion date December 31, 2027
Est. primary completion date June 15, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Voluntarily signed consent; - Age of = 18; - Willing and able to adhere to trial visit schedule and other protocol requirements - Received sufficient prior lines of therapy; - RRMM participants must have received treatment with at least one proteasome inhibitor, one IMiD and CD38 anti body, must be refractory to the last line of therapy, must have achieved a response (PR or better) to a least 1 prior treatment line; - RRpPCL participants must have received at least one prior line of therapy. - Participants must have documented diagnosis of RRMM or RRpPCL. - The participants should have measurable disease. - Estimated life expectancy > 12 weeks; - ECOG performance score 0-1; - Participants should have bone marrow reserve, renal and hepatic functions; - Sufficient venous access for apheresis collection, and no other contraindications to apheresis; - Must be able to stop any anticancer therapy for planned apheresis collection - Women of childbearing age must undergo a serum pregnancy test with negative results before screening, and are willing to use effective and reliable method of contraception for at least 12 months after T cell infusion; - Men must be willing to use effective and reliable method of contraception for at least 12 months after T cell infusion. Exclusion Criteria: - Any significant condition(s), laboratory abnormality or psychiatric illness that would impair the ability of the participant to receive or tolerate the planned treatment or in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments. - Pregnant or lactating women; - HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infection; - Any uncontrolled active infection; - AEs from previous treatment that have not recovered; - Participants who have had anti-GPRC5D targeted agents; - Participants who have received autologous stem cell transplantation 12 weeks before apheresis; - Participants who have received allogenic stem cell transplantation within 6 months of apheresis; - Participants who have graft versus host disease (GvHD); - Participants who have received steroids within 14 days of apheresis or lymphodepletion; - Participants who have plasma cell leukemia secondary to multiple myeloma, Waldenström macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome or clinically significant symptomatic immunoglobulin light chain (AL) amyloidosis with evidence of end-organ damage; - Participants who have been administered live attenuated vaccine 4 weeks before apheresis or lymphodepletion; - Participants who are allergic to fludarabine, cyclophosphamide, tocilizumab, dimethyl sulfoxide (DMSO) or CT071; - Participants who have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients; - Participants who require supplemental oxygen; - Participants who have clinically significant pulmonary conditions; - Participants who are known to have active autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis and other needs of long-term immunosuppressive therapy; - Participants with malignancies in addition to MM/pPCL; - Participants who have central nervous system (CNS) metastases or CNS involvement; - Participants with a history of stroke or seizures within 6 months prior to apheresis; - Participants who have undergone major surgery 14 days prior to apheresis or within 28 days of CT071 administration.

Study Design


Intervention

Biological:
CT071
a single CAR-T infusion of CT071

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
CARsgen Therapeutics Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1: Evaluation of the Safety of CT071 and determination of Maximum Tolerated Dose (MTD). Frequency, type, and severity of AEs (SAEs, AESIs, laboratory abnormalities). Day 1 - Month 24
Primary Phase 2: Objective response rate Objective response rate (ORR) per IMWG by IRC read; percentage of participants achieving confirmed PR or better per IMWG 2016 consensus criteria. Day 1 - Month 24
Secondary Phase 1 and 2: Evaluate additional clinical efficacy outcomes Overall Response Rate/Best Overall Response Rate by investigator (by IMWG stringent complete response/sCR, complete response/CR, very good partial response/VGPR, and partial response/PR by IRC and investigator assessment). Day 1 - Month 24
Secondary Phase 1 and 2: Evaluate additional clinical efficacy outcomes Duration of Response by IMWG (stringent complete response/sCR, complete response/CR, very good partial response/VGPR, and partial response/PR by IRC and investigator assessment). Day 1 - Month 24
Secondary Phase 1 and 2: Evaluate additional clinical efficacy outcomes Progression Free Survival by investigator assessment Day 1 - Month 24
Secondary Phase 1 and 2: Evaluate additional clinical efficacy outcomes Overall Survival Day 1 - Month 24
Secondary Phase 2: Evaluate additional Safety of CT071. Frequency, type, and severity of AEs (SAEs, AESIs, laboratory abnormalities). Day 1 - Month 24
Secondary Phase 1 and 2: Assess immunogenicity of CT071 Percentage of patients with anti-CT071 drug antibodies Day 1 - Month 60
Secondary Phase 1 and 2: Evaluate PK profile of CT071 CAR transgene copy peak value Day 1 - Month 60
Secondary Phase 1 and 2: Evaluate PK profile of CT071 CAR transgene copy number persistence Day 1 - Month 60
Secondary Phase 1 and 2: Evaluate PK profile of CT071 CAR transgene copy AUC Day 1 - Month 60
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1